Janus Henderson Group
EGRX

Janus Henderson Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Janus Henderson Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-775,525
Closed -$4.06M – 2585
2023
Q4 		$4.06M Sell
775,525
-365,848
-32% -$3.61M ﹤0.01% 907
2023
Q3 		$18M Sell
1,141,373
-6,398
-0.6% -$115K 0.01% 556
2023
Q2 		$22.3M Sell
1,147,771
-658
-0.1% -$15.6K 0.01% 540
2023
Q1 		$32.6M Sell
1,148,429
-81,443
-7% -$2.42M 0.02% 472
2022
Q4 		$35.9M Sell
1,229,872
-1,249,686
-50% -$39.7M 0.03% 447
2022
Q3 		$65.5M Buy
2,479,558
+1,042,244
+73% +$38.2M 0.02% 455
2022
Q2 		$63.9M Sell
1,437,314
-48,090
-3% -$2.21M 0.04% 329
2022
Q1 		$73.5M Sell
1,485,404
-42,748
-3% -$2.05M 0.04% 400
2021
Q4 		$77.8M Buy
1,528,152
+1,050
+0.1% +$54.4K 0.03% 417
2021
Q3 		$85.2M Sell
1,527,102
-3,375
-0.2% -$166K 0.04% 393
2021
Q2 		$65.5M Sell
1,530,477
-60,233
-4% -$2.49M 0.03% 498
2021
Q1 		$66.4M Sell
1,590,710
-103,363
-6% -$4.8M 0.03% 472
2020
Q4 		$78.9M Sell
1,694,073
-4,664
-0.3% -$218K 0.04% 424
2020
Q3 		$72.2M Sell
1,698,737
-7,907
-0.5% -$346K 0.04% 404
2020
Q2 		$81.9M Sell
1,706,644
-52,850
-3% -$2.64M 0.05% 362
2020
Q1 		$80.9M Sell
1,759,494
-40,215
-2% -$2.02M 0.06% 326
2019
Q4 		$108M Buy
1,799,709
+33,909
+2% +$2.02M 0.06% 345
2019
Q3 		$99.9M Sell
1,765,800
-2,354
-0.1% -$132K 0.05% 368
2019
Q2 		$98.5M Sell
1,768,154
-5,098
-0.3% -$266K 0.05% 377
2019
Q1 		$89.5M Sell
1,773,252
-22,210
-1% -$988K 0.05% 410
2018
Q4 		$72.3M Sell
1,795,462
-86,039
-5% -$4.43M 0.05% 439
2018
Q3 		$130M Sell
1,881,501
-9,797
-0.5% -$743K 0.07% 329
2018
Q2 		$143M Sell
1,891,298
-15,062
-0.8% -$948K 0.08% 293
2018
Q1 		$100M Buy
1,906,360
+245,479
+15% +$14.3M 0.06% 372
2017
Q4 		$88.7M Sell
1,660,881
-146,321
-8% -$8.14M 0.05% 396
2017
Q3 		$108M Sell
1,807,202
-22,997
-1% -$1.39M 0.07% 347
2017
Q2 		$144M Buy
+1,830,199
New +$150M 0.1% 264

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Janus Henderson Group's EGRX Position: Q1 2024 in Review

Janus Henderson Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 775,525 shares — an estimated $4.06M sold.

Janus Henderson Group first reported a position in EGRX in Q2 2017 and held it in 27 quarters. The position peaked at $144M in Q2 2017. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.

  • Janus Henderson Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Janus Henderson Group sold 775,525 Eagle Pharmaceuticals, Inc. shares in Q1 2024, an estimated $4.06M.
  • Janus Henderson Group first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2017 and held it in 27 quarters.
  • Janus Henderson Group's Eagle Pharmaceuticals, Inc. position peaked at $144M in Q2 2017.
  • 91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.

Based on Janus Henderson Group's 13F filing for Q1 2024, filed 15 May 2024.